文献速递毛发、甲与色素性疾病

Ritlecitinib治疗斑秃24个月疗效与安全性:ALLEGRO IIb/III及长期III期整合分析

Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.
PubMed 文献 · Br J Dermatol · 2025-01-01

该研究整合ALLEGRO IIb/III与长期开放标签III期ALLEGRO-LT研究,评估Ritlecitinib在≥12岁、头皮脱发≥50%的斑秃患者中至24个月的疗效与安全性。结果显示,50mg每日组第12个月SALT≤20达45.1%(观察值),第24个月升至60.8%,安全性与已知特征一致。

要点

  • Ritlecitinib 50mg组第24个月SALT≤20观察值达60.8%,疗效持续超过1年。
  • 眉毛和睫毛评估应答率在24个月时亦提升,患者满意度约8/10。
  • 安全性特征与既往研究一致,支持≥12岁斑秃患者长期使用。

核心结论

  • Ritlecitinib在≥12岁斑秃患者中具有临床意义且持续的疗效,安全性和耐受性良好,支持长期使用。

研究设计与样本

  • 整合ALLEGRO IIb/III研究(NCT03732807)与正在进行的长期开放标签III期ALLEGRO-LT研究(NCT04006457)。
  • 纳入≥12岁、头皮脱发≥50%且完成ALLEGRO IIb/III至48周后转入ALLEGRO-LT的患者。
  • 分析Ritlecitinib 50mg每日(伴或不伴200mg 4周负荷剂量)至第24个月的数据。

主要发现

  • 第12个月SALT≤20:50mg组191例中45.1%(观察值)、40.3%(LOCF);200/50mg组194例中45.9%(观察值)、41.8%(LOCF)。
  • 第24个月SALT≤20升至:50mg组60.8%(观察值)、46.1%(LOCF);200/50mg组63.1%(观察值)、50.8%(LOCF)。
  • 基线EBA异常者第24个月应答:50mg组57.6%(观察值)、46.8%(LOCF);200/50mg组61.0%(观察值)、50.9%(LOCF)。
  • 基线ELA异常者第24个月应答:50mg组51.2%(观察值)、43.2%(LOCF);200/50mg组62.7%(观察值)、51.7%(LOCF)。
  • 第24个月PGI-C应答:50mg组70.0%(观察值)、56.6%(LOCF);200/50mg组76.4%(观察值)、65.5%(LOCF)。

关键数值与推荐

  • 疗效主要指标为SALT评分≤20和≤10、眉毛评估(EBA)、睫毛评估(ELA)、患者整体印象变化(PGI-C)及对毛发生长的满意度。
  • 安全性评估贯穿研究全程,两治疗组安全特征与Ritlecitinib已知安全性一致。

临床怎么用

  • Ritlecitinib 50mg每日(可伴200mg 4周负荷)可用于≥12岁重度斑秃患者,长期治疗可持续改善头皮及眉毛/睫毛毛发再生。
  • 治疗决策中可参考24个月持续应答数据,并向患者说明安全性特征与既往一致。

局限性

  • 长期数据来自开放标签扩展研究,观察值与LOCF分析并存,可能存在缺失数据影响。
  • 数据截止至2022年12月9日,更长随访结果有待进一步报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ALLEGRO phase IIa and IIb/III (NCT02974868 and NCT03732807) studies have demonstrated that ritlecitinib is effective and well tolerated in adults and adolescents with alopecia areata (AA) up to 48 weeks. OBJECTIVES: To assess the efficacy of ritlecitinib through month 24 and safety through data cutoff in the ALLEGRO phase IIb/III study and the ongoing long-term open-label phase III ALLEGRO-LT study (NCT04006457). METHODS: Patients aged ≥ 12 years with AA and ≥ 50% scalp hair loss from ALLEGRO IIb/III who rolled over to ALLEGRO-LT after up to 48 weeks were included. Proportions of patients with responses based on clinician-reported Severity of Alopecia Tool (SALT) scores of ≤ 20 and ≤ 10, eyebrow assessment (EBA) and eyelash assessment (ELA), patient global impression of change (PGI-C) and patient satisfaction with hair growth were reported through month 24 for patients who received ritlecitinib 50 mg daily with or without a 200-mg 4-week daily loading dose. Observed and imputed data [last observation carried forward (LOCF)] were reported up to 9 December 2022. Safety was assessed throughout. RESULTS: At month 12, a SALT score ≤ 20 was achieved by 45.1% and 45.9% (observed) and 40.3% and 41.8% (LOCF) of the 191 and 194 patients who received ritlecitinib 50 mg and ritlecitinib 200 mg/50 mg, respectively. At month 24, these proportions increased to 60.8% and 63.1% (observed) and 46.1% and 50.8% (LOCF), respectively. Patients with abnormal EBA or ELA scores at baseline achieved responses at month 24 [EBA observed: 57.6% (50 mg), 61.0% (200/50 mg); EBA LOCF: 46.8% (50 mg), 50.9% (200/50 mg); ELA observed: 51.2% (50 mg), 62.7% (200/50 mg); ELA LOCF: 43.2% (50 mg), 51.7% (200/50 mg)]. PGI-C response was achieved by patients at month 24 [observed: 70.0% (50 mg), 76.4% (200/50 mg); LOCF: 56.6% (50 mg), 65.5% (200/50 mg)]. Safety profiles for both treatment groups were consistent with the known safety profile of ritlecitinib. CONCLUSIONS: Ritlecitinib has clinically meaningful and sustained efficacy beyond 1 year with a favourable safety and tolerability profile, supporting its long-term use in patients aged ≥ 12 years with AA. Alopecia areata is a condition where the immune system mistakenly attacks hair follicles, causing hair loss. It affects around 2% of people worldwide, including children and adults. Alopecia areata may involve small patches or complete hair loss on the scalp and/or body. People with alopecia areata may need to use medicines for a long time to manage hair loss. There are not many treatment options available. Ritlecitinib is a pill taken daily to treat severe alopecia areata. It blocks the steps that cause hair loss. In this study, we looked at how well ritlecitinib worked over 2 years in people aged 12 years and older with alopecia areata who had lost at least half of their scalp hair. We measured hair loss on the scalp, eyebrows and eyelashes, as well as how satisfied people were with their hair regrowth. We also looked at how safe ritlecitinib was when taken for 2 years. A total of 191 people from 17 countries took the approved dose of ritlecitinib. After 1 year, 74 of 164 people (45%) had scalp hair regrowth (20% or less scalp hair loss), increasing to 61% after 2 years. For every 8 out of 10 people, their scalp hair regrowth was maintained from 1 to 2 years. Eyebrow and eyelash hair regrowth also increased over 2 years. Around 8 out of 10 people were satisfied with their hair growth after 2 years, and the safety of ritlecitinib was as expected from the studies done before. The results show that ritlecitinib is effective and appropriate for long-term use in people aged 12 years and older with alopecia areata.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Piliang M, Soung J, King B, et al. Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025. PMID: 39432738. doi:10.1093/bjd/ljae365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。